Virtual Library
Start Your Search
Lior Apter
Author of
-
+
EP1.01 - Advanced NSCLC (ID 150)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.01-21 - Time on Treatment of First-Line PD-1 Inhibitor Monotherapy for Metastatic Non-Small Cell Lung Cancer Patients: Real-World Experience Data (Now Available) (ID 764)
08:00 - 18:00 | Author(s): Lior Apter
- Abstract
Background
Clinical trials have established the role of immune checkpoint inhibitors for metastatic NSCLC treatment, but real-world data are limited. We describe the first report of a prospective study on real-world time on treatment (rwTOT) for first-line (1L) anti-PD-1 monotherapy in metastatic NSCLC in a 2.3 million member public health provider in Israel.
Method
Newly diagnosed stage IV NSCLC patients who initiated 1L anti-PD-1 therapy in 2017 were identified from the national cancer registry. rwTOT was defined as the length of time between first and last administration date of anti-PD-1 therapy. Patients were considered discontinued if they had a record of next line of therapy, or death, or whose last activity date was ≥120 days from the last administration date; others were censored. The Kaplan-Meier (KM) median and restricted mean (rMean) rwToT were estimated. Jun 2018 data cutoff was utilized to allow minimum 6 months follow-up.
Result
A total of 63 patients initiated 1L anti-PD-1 monotherapy; of these, 59 were PD-L1 TPS≥50%, one was TPS<50% and 3 unknown. This cohort comprised of 97% pembrolizumab monotherapy, 65% males, median age=59 yrs, 76% ever smokers, 71% adenocarcinomas, 11% brain metastases, and 62%/14%/24% with 0-1/2-4/unknown ECOG status. The median rwToT was 4.6 (95% CI 2.8-12.8) mo and estimated rMean at 24 months using parametric extrapolation was 10.9 mo (4.3-16.8). Patients with ECOG 0-1, n=39, had a median rwTOT of 10.6 mo (1.9-19.2).
Time on treatment for anti-PD-1 monotherapy
Conclusion1L anti-PD-1 Monotherapy
N=63
1L Pembrolizumab Monotherapy
N=61
N discontinued (%)
38 (60.3)
36 (59.0)
KM Median rwToT (95% CI)
4.6 (2.8-12.8)
5.0 (3.5-NE)
rMean rwToT @ 12 months (95% CI)
6.5 (5.3-7.7)
6.7 (5.4-7.9)
Parametric (extrapolated) rMean rwToT @ 24 months (95% CI)
10.9 (4.3-16.8)
[Gompertz]
11.2 (4.4-17.1)
[Gompertz]
6 months on treatment rate, % (95% CI)
44.1 (31.6-55.9)
45.5 (32.7-57.5)
12 months on treatment rate, % (95% CI)
39.7 (27.3-51.9)
41.0 (28.3-53.4)
The results of this unselected real-world cohort of metastatic NSCLC patients treated with 1L anti PD-1 monotherapy show that rwTOT rates compare favorably with published data from clinical trials and other real-world studies.
